Replies to post #226244 on Biotech Values

[jbog]

By my arithmetic, ENTA would be EPS-accretive immediately to certain prospective suitors at a price as high as $110/sh, making reasonable assumptions about cost synergies and tax rates. (One of the “cost synergies” might be axing the NASH program.)

There's no math that could set a price with knowledge of the variables. Enta's Income stream is a solid plus but it's been the explosion of spending that has created the current senerio.

As of now, Enta's endeavors into other fields are nothing but a waste of lucrative income.

[mr_o]

What is the case for continuing to own ENTA as a stand alone company at this valuation, other than buy out vig?